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Sinai, New York, NY
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Abstract
Background—Collagen cross-linking is mediated by lysyl oxidase (LOX) enzyme in the 
extracellular matrix (ECM) of mitral valve leaflets. Alterations in collagen content and LOX 
protein expression in the ECM of degenerative mitral valve may enhance leaflet expansion and 
disease severity.
Methods—Twenty posterior degenerative mitral valve leaflets from patients with severe mitral 
regurgitation were obtained at surgery. Five normal posterior mitral valve leaflets procured during 
autopsy served as controls. Valvular interstitial cells (VICs) density was quantified by 
immunohistochemistry, collagen types I and III by picro-sirius red staining and 
immunohistochemistry, and proteoglycans by alcian blue staining. Protein expression of LOX and 
its mediator TGFβ1 were quantified by immunofluorescence and gene expression by PCR.
Results—VICs density was increased, structural type I collagen density was reduced, while 
reparative type III collagen and proteoglycan densities were increased (p<0.0001) with an increase 
in spongiosa layer thickness in myxomatous valves. These changes were associated with a 
reduction in LOX (p<0.0001) and increase in TGFβ1 protein expression (p<0.0001). However, no 
significant change was seen in gene expression. Linear regression analysis identified a correlation 
between type I collagen density and LOX grade (R2=0.855; p<0.0001).
Conclusions—Reduced type I collagen density with a simultaneous increase in type III collagen 
and proteoglycan densities possibly contributes to spongiosa layer expansion resulting in 
incompetent mitral valve leaflets. Observed changes in type I and III collagen densities in DMVD 
may be secondary to alterations in LOX protein expression, contributing to disorganization of 
ECM and disease severity.
*Address for correspondence: K- Raman Purushothaman MD, FAHA, Assistant Professor of Medicine/Cardiology/Pathology, Icahn 
School of Medicine at Mount Sinai, Cardiovascular Institute, One Gustave Levy Place, Box 1030, New York, NY 10029, Telephone: 
212-241-9782; Fax: 212-241-4080, purushothaman.kothandaraman@mountsinai.org. 
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1. INTRODUCTION
Degenerative mitral valve disease (DMVD) complicated by severe mitral regurgitation 
(MR), is a major cause of cardiovascular morbidity and mortality [1]. Degenerative lesions, 
such as chordal elongation, chordal rupture and leaflet expansion lead to mitral valve 
dysfunction that may necessitate surgical repair if severe regurgitation results [2, 3]. These 
lesions are related to altered production of extracellular matrix (ECM), including collagens 
and proteoglycans [4, 5]. Valvular interstitial cells (VICs) that include fibroblasts, smooth 
muscle cells and myofibroblasts are responsible for ECM production [6, 7]. Tissue injury 
due to mechanical or structural alteration may trigger proliferation and differentiation of 
fibroblasts into contractile and secretory myofibroblasts that facilitate tissue remodeling [6]. 
The distinction between normal and pathological degenerative valves depends on the 
composition and maturation of its ECM components. Collagens play a major role in leaflet 
stability and during post-translational modification, the collagen protein maturation occurs 
through cross-linking. Lysyl oxidases (LOX) are a family of matrix remodeling extracellular 
enzymes that catalyze the cross-linking of collagens and elastin thereby contributing to the 
maturation of ECM [8]. Such crosslinks result in the formation of thick collagen polymers 
that provide tensile strength to valve leaflets [4]. LOX is crucial for the maturation of ECM, 
as evidenced by experimental models which are deficient in LOX and have shown defective 
ECM [9–12]. We tested the hypothesis that altered collagen composition in DMVD may be 
associated with a reduction in LOX protein expression. We compared the ECM components 
including type I and type III collagens, proteoglycan densities and LOX protein expression, 
in degenerative mitral valve leaflets obtained from patients with severe mitral regurgitation 
and normal mitral valves identified at autopsy.
2. METHODS
2.1 Sample collection
Twenty prolapsed posterior mitral valve leaflets were collected from patients who underwent 
surgical mitral valve repair for severe MR at Mount Sinai Hospital, New York. Five normal 
posterior mitral valve leaflets, collected from autopsies performed on patients who died of 
non-cardiac conditions, served as controls. The surgical and autopsy specimens were 
collected from the P2 segment of the posterior mitral valve leaflet, and immediately fixed in 
10% formalin solution. Following fixation, 2–3 mm thick sections of the mitral valve leaflet 
of each case were cut perpendicularly from the annular margin to the free edge margin, and 
processed into paraffin blocks on the same day. The samples were oriented for paraffin 
sectioning from the base to the free edge of the leaflet. In addition to specimens fixed in 
formalin, a small portion of the specimen was freshly frozen, stored at −80°C and later 
processed for RNA extraction. Pertinent demographic and clinical data were collected from 
medical records. This study was approved by the Institutional Review Board at Icahn School 
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of Medicine at Mount Sinai. Informed consent was obtained from all patients and 
experiments were conducted per the guidelines of the Declaration of Helsinki principles.
2.2 Quantification of valvular interstitial cells density
Deparaffinized valve tissue sections (5 μm) were incubated with specific primary antibody 
using muscle actin monoclonal (C-34931, Enzo, NY) at 1:30 dilution, rabbit polyclonal to 
vimentin (ab-45939, Abcam, MA) at 1:100 dilution, and rabbit polyclonal to fibroblast 
specific protein-1 (FSP-1) (ab-27957, Abcam, MA) at 1:100 dilution; and 
immunohistochemistry was performed using avidin-biotin complex- Elite ABC Vectastain 
kit (Vector Lab, CA) as described by the manufacturer’s instruction. The protein expression 
was detected by developing with 3′3′-diaminobenzidine chromogen. The cell density was 
calculated by dividing the number of positive cells by total cell area in 20X high power field 
(HPF), as previously published [13]. All images from the histological samples in this study 
were obtained with an Olympus BX50 microscope and the computerized analysis of the 
images was performed using the QuantIm (ZEDEC Technologies, Inc) software, except 
where described. Appropriate control tissues were stained along with test samples by 
substituting primary antibody for IgG or specific IgG isotypes from the same species and at 
the same final concentration as the primary antibody [14]. Quantification included all the 
three valve layers: atrialis, spongiosa and ventricularis. All measurements were done from 
the base to the free edge of the leaflet section.
2.3 Quantification of collagen and proteoglycan density
Deparaffinized valve tissue sections (5 μm) were used to measure type I and III collagen 
densities using picro-sirius red stain and evaluated with polarized microscopy as previously 
published [15]. Furthermore, specific immunohistochemistry was performed using anti-
collagen I antibody (ab90395, Abcam, MA), at 1:100 dilution; and anti-collagen III antibody 
(ab7778, Abcam, MA), at 1:200 dilution. Appropriate positive and negative controls for type 
I and III collagen were included using human uterine tissue. Collagen density was measured 
with computerized planimetry [15] and graded the area stained by collagen as follows: grade 
0: no stain; grade 1: upto 25 % positive; grade 2: >26–50% positive; and grade 3: >50% 
positive stained area. To measure proteoglycans, valve tissue sections were stained with 1% 
alcian blue at pH2.5 per manufacturer’s instruction (Polyscientific, NY), imaged with 20X 
objective, and the proteoglycan density was evaluated using computerized digital planimetry 
by measuring the proteoglycan stained area, divided by the total valve area measured.
2.4 Quantification of thickness of histological layers of mitral valve leaflet
Using hematoxylin and eosin (H&E) stained sections, the thickness and composition of each 
of the histological layers of mitral valve leaflets were analyzed separately and compared 
among each other. The following parameters were measured: 1) atrialis layer thickness, 2) 
spongiosa layer thickness, and 3) ventricularis layer thickness. The expansion of spongiosa 
layer and infiltration into ventricularis was semi quantitatively scored (Grade 0–3). Grade 0: 
no expansion of spongiosa layer; grade 1: mild expansion (≤25%); grade 2: moderate 
expansion (25–75%); and grade 3: showing severe expansion (≥75%) with infiltration into 
ventricularis layer.
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2.5 Quantification of LOX and TGFβ protein expression
Deparaffinized tissue sections (5μm) were incubated with specific primary rabbit polyclonal 
anti-LOX propeptide (Novus biologicals, CA), at 1:100 dilution. Immunohistochemistry was 
performed and evaluated as described previously (section 2.2). Appropriate positive and 
negative controls using human liver tissue were included to distinguish non-specific binding. 
The level of LOX protein expression was graded as per the area stained by LOX as follows: 
grade 0: no stain; grade 1: upto 25% positive; grade 2: >26–50% positive; grade 3: >50% 
positive stained area. Furthermore, LOX expression was also confirmed by 
immunofluorescence using the same primary antibody with a secondary donkey anti-rabbit 
Alexa Fluor 594 (A-21207, Invitrogen, CA) at 1:250 dilution. Images were acquired using 
Leica TCS SP5 DMI confocal microscope and analyzed using ImageJ software (NIH). 
Using specific mouse monoclonal antibody for TGFβ1 (Abcam, MA) the density of TGFβ1 
was quantified using immunofluorescence as described above for LOX quantification.
2.6 Quantification of gene expression of collagens, LOX and TGFβ1
Total RNA was isolated from mitral valve leaflets, as previously reported [16]. The RNA 
concentration was quantified using Nanodrop and reverse transcribed to cDNA using 
TaqMan reverse transcription reagents (Applied Biosystems, CA). The cDNA was used to 
measure the mRNA expression by quantitative real-time PCR with specific primer sequence 
for collagen I (Col1A1), frd: 5′-gattccctggacctaaaggtgc-3′ and rev: 5′-
agcctctccatctttgccagca-3′; collagen-III (COL3A1), frd: 5′-tggtctgcaaggaatgcctgga-3′ and 
rev: 5′-tctttccctgggacaccatcag-3′; LOX, frd: 5′-gatacggcactggctacttcca-3′ and rev: 5′-
gccagacagttttcctccgcc-3′; and TGFβ1, frd: 5′-gcagcacgtggagctgta-3′; and rev: 5′-
cagccggttgctgaggta-3′. The mRNA expression was normalized to the house keeping gene 
beta actin.
2.7 Statistical analysis
Data are presented as mean ± SEM. For 2-group comparisons, Gaussian distribution samples 
were compared by 2-tailed Student t test, preceded by Levene F test for equality of 
variances. Non-Gaussian-distribution samples were compared by Mann-Whitney 
nonparametric test. For multiple comparisons, one-way ANOVA was used. The following 
variables were included in the analysis: sex, diabetes mellitus, hypertension, coronary artery 
disease, smoking, (dichotomous variables); severity of myxoid area infiltration grade, 
(ordinal variables with values of 0, 1, 2, 3); age, blood glucose levels, body mass index, 
atrialis layer thickness, spongiosa layer thickness, ventricularis layer thickness, type I and III 
collagen density, proteoglycan density, FSP-1, vimentin and α-actin densities, gene 
expression of type I and III collagens, LOX, and TGFβ1 (continuous variables). IBM SPSS/
PASW Statistics 20 (SPSS Inc. Chicago, Illinois) software was used for the analysis. p-value 
<0.05 was considered significant.
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3. RESULTS
3.1 Demographic and clinical profile
Demographic and clinical profiles were similar between DMVD and control (normal) group 
(Table 1). There was no statistically significant difference in age, sex, prevalence of diabetes 
mellitus, hypertension, coronary artery disease and smoking between the groups (p>0.2). 
There were no reports of rheumatic or infective endocarditis etiology among the studied 
cases. All subjects with DMVD corresponded to degenerative, non-syndromic, non-ischemic 
etiologies. All subjects in DMVD group had severe mitral regurgitation according to 
echocardiography evaluation; six of them (30%) presented with chordae rupture, and their 
distribution according to New York Heart Association (NYHA) Functional Classification 
was: class II = 7(35%), class III = 12(60%), class IV = 1(5%); left ventricular ejection 
fraction (LVEF) was >59% in 12 patients (60%) and 40–59% in 8 patients (40%).
3.2 Valvular interstitial cells density
VICs (fibroblast, myofibroblast and smooth muscle cell) density was significantly increased 
in degenerative mitral valve leaflets compared to control leaflets; FSP-1 (163 ± 5 vs 41 
± 6.5; p<0.0001), vimentin (114 ± 4 vs 46.7 ± 2; p<0.0001) and α-actin (90.5 ± 3.4 vs 46 
± 4; p<0.0001) (Figure 1).
3.3 ECM composition: type I and III collagen and proteoglycan density
The picro-sirius red staining analysis showed a significant decrease in structural type I 
collagen density in degenerative mitral valve leaflets compared to control (0.17 ± 0.01 vs. 
0.66 ± 0.01; p<0.0001), whereas, reparative type III collagen density was significantly 
increased in degenerative mitral valve leaflets (0.49 ± 0.02 vs.0.18 ± 0.01; p<0.0001) 
(Figure 2A–D). Immunohistochemistry evaluation of type I and type III collagen showed a 
similar result with a significant decrease in type I collagen (0.85 ± 0.17 vs. 2.8 ± 0.07; p= 
0.0001) and an increase in type III collagen (2.7 ± 0.06 vs. 0.9 ± 0.06; p= 0.0001) in 
degenerative mitral valve leaflets compared to control (Figure 2E–J). Proteoglycan density 
was also significantly increased in degenerative mitral valve leaflets compared to control 
(0.5 ± 0.03 vs. 0.16 ± 0.02; p<0.0001) (Figure 3A–C).
3.4 Histological layer thickness and spongiosa layer expansion
The spongiosa layer thickness was significantly increased in degenerative mitral valve 
leaflets compared to control (983 ± 87 μm vs. 63 ± 8.9 μm; p<0.0001) (Figure 3D–F). The 
atrialis layer thickness was moderately increased, whereas, there was no significant change 
in the ventricularis layer thickness (Table 2). The myxoid region of the spongiosa layer 
expansion was seen to extend and infiltrate into the ventricularis layer only in degenerative 
mitral valve leaflets, whereas, there was no infiltration in control mitral valve leaflets. The 
infiltration into the ventricularis layer paralleled with the histological severity of DMVD. 
This was demonstrated by correlating increased spongiosa layer thickness to histological 
grade severity of infiltration of spongiosa layer into ventricularis layer (Figure 4).
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3.5 LOX and TGF-β1 protein and gene expression
LOX expression was significantly decreased in degenerative mitral valve leaflets compared 
to control (0.46 ± 0.07 vs 2.4 ± 0.22; p<0.0001) (Figure 5A–C). Immunofluorescent images 
further confirmed that LOX expression was reduced in degenerative mitral valve leaflets, 
despite an increase in cellular content (DAPI staining) (Figure 5D–E). In addition, linear 
regression analysis identified a correlation between type I collagen density and LOX grade 
(r2 =0.855; p<0.0001) (Figure 5F). The TGFβ1 protein expression was significantly 
increased in degenerative mitral valve leaflets compared to control mitral valve leaflets (4.5 
± 0.39 vs 1.08 ± 0.04; p<0.0001) (Figure 5G–I). There was no significant change in gene 
expression of type I collagen (1.9 ± 0.18 vs 3.22 ± 0.49; p=NS), type III collagen (1.78 ± 0.2 
vs 1.6 ± 0.56; p=NS), LOX (4.25 ± 0.26 vs 3.3 ± 0.45; p=NS) and TGFβ1 (5.75 ± 0.08 vs 
5.56 ± 0.45; p=NS) in degenerative mitral valve leaflets compared to control.
4. DISCUSSION
DMVD is considered to be a potential cause of mitral valve prolapse resulting in mitral 
regurgitation (MR) [17]. Advanced DMVD with rupture of chordae tendineae leads to severe 
MR and clinically presents with cardiac decompensation [18, 19]. Valvular leaflet expansion 
caused by enhanced VICs and production of altered extracellular matrix (ECM) in the 
spongiosa layer seems to facilitate the lesion progression in DMVD [20]. Structural 
alterations in the cellular and ECM are possibly due to associated modifications of 
regulatory enzymes and growth factors. We have here investigated a pathological association 
of cellular density and altered ECM proteins in advanced DMVD, which could have 
implications in disease progression.
In the present study, we observed in degenerative mitral valve leaflets an increased density 
of VICs associated with excessive production of ECM, including altered collagen and 
increased proteoglycan deposition (Figure 6). This is in accordance to previous studies, 
which have documented proliferation of VICs leading to increased ECM in DMVD [21, 22]. 
When quantifying distinct collagen types, the structural type I collagen was significantly 
decreased, whereas, immature type III collagen was significantly increased. To explore the 
mechanisms involved in the reduction of type I collagen, we quantified the cross-linking 
enzyme LOX. The protein expression of LOX was reduced, pointing to a correlation to the 
observed decrease in type I collagen density. Simultaneously, we observed an increase in 
type III collagen and proteoglycan content resulting in increased spongiosa layer thickness. 
This suggests a reparative or compensatory mechanism that resulted in disorganized ECM 
composition. Excessive production of proteoglycan interferes with the normal assembly of 
collagen fibrils and remodeling [23] and may be responsible for improper assembly of 
collagen fibers resulting in severe mitral regurgitation.
During collagen synthesis, collagen molecules undergo several post-translational 
modifications that facilitate their cross-linking and consequently the formation of collagen 
fibers. A key enzyme in this process is LOX, which initiates lysine and hydroxylysine-
derived cross-linking of fibrillar collagen molecules such as type I collagen [11, 24, 25]. The 
significant decrease in type I collagen density observed in this study indicates impairment in 
the formation of thick functional type I collagen fibers. Whereas, type III collagen is more 
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extensible, weaker and immature than thick structural type I collagen; and the synthesis of 
type III collagen occur in response to injury [26], independent of LOX. Collagen tensile 
strength mainly relies on the cross-linking; and, it is considered that not only the content of 
collagen, but its cross-linking which has an impact on stiffness [27]. LOX gene expression 
was not altered in this study; however, the decrease in LOX protein expression is suggestive 
of alterations in post-translational modification. LOX is synthesized as a pre-protein and 
after signal peptide hydrolysis, glycosylation, copper incorporation, and lysine 
tyrosylquinone generation, the enzyme is released into ECM, where it is processed to form 
mature LOX [28]. Any defect in post-translational modification results in defective LOX 
expression and activity. These data suggest that LOX plays a key role in the formation of 
cross-linked type I collagen fibers. Furthermore, no significant change in the gene 
expression of type I and type III collagen was observed in this study and no mutations in 
genes coding for collagen have been reported in DMVD [29].
Finally, TGFβ is known to interact with ECM components and has been shown to be 
implicated in both familial and syndromic mitral valve prolapse [30]. LOX, being a key 
regulator of ECM maturation modulates TGFβ activation. It has been reported that absence 
or reduced LOX activity augments TGFβ signaling, demonstrating that LOX attenuates 
TGFβ signaling [31]. Also, it has been described that when LOX expression/activity is 
reduced, the subsequent inefficient cross-linking of collagens, results in reduction of their 
tensile strength and interestingly also increases their solubility, and thereof higher propensity 
to proteolysis, possibly responsible for augmentation of TGFβ in the tissue [32]. Although 
more experimentation is required on both signaling pathways, based on our findings, we 
report low levels of LOX in association with reduction in type I collagen density in DMVD 
results in leaflet instability and severe mitral valve disease.
This is an observational study correlating an association of LOX with ECM changes, 
without establishing an actual causation for mitral valve degeneration, which is a limitation 
of this study. Also, blood samples were not available to investigate enzyme activity; and 
acquisition of samples to serve as control was restricted by the number of specimens from 
autopsy. However, our study documents crucial alterations in type I collagen density and 
LOX expression with ECM disorganization in DMVD.
5. CONCLUSION
In this study, we have documented an increase in VICs density associated with excessive 
production of ECM components. Reduction in thick type I collagen density associated with 
compensatory increase in type III collagen and proteoglycan deposition may be related to 
impaired cross-linking of type I collagen mediated by LOX. These changes also contribute 
to a derangement of the ECM composition, leading to increased spongiosa layer thickness, a 
histological marker of mitral valve disease severity.
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Highlights
• Lysyl oxidase enzyme mediates collagen cross-linking in the extracellular 
matrix.
• Reduced Lysyl oxidase may alter type I and type III collagens in spongiosa 
layer.
• Spongiosa layer expansion may enhance leaflet instability and disease 
severity.
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Figure 1. 
Valvular interstitial cell density in posterior degenerative mitral valve leaflets compared to 
control. Representative images from immunohistochemical staining with primary antibodies 
chosen to detect (A,B) fibroblast (FSP-1), (D,E) myofibroblasts (vimentin), and (G,H) 
smooth muscle cells (α-actin); scale bar = 50μm. Corresponding bar graphs show 
quantification of positive cells per high power field for FSP-1 (C), vimentin (F) and α-actin 
(I).
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Figure 2. 
Type I and III collagen density in degenerative mitral valve leaflets compared to control. 
Representative images of picro-sirius red stained sections from DMVD (A) and control (B) 
posterior mitral valve leaflets and corresponding quantification of collagen density measured 
with polarized microscopy (C,D). Representative immunohistochemistry images for type III 
(E,F) and type I (G,H) collagens; and corresponding measurement of collagen abundance by 
grade (I,J). Scale bar = 50μm.
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Figure 3. 
Proteoglycan expression in degenerative mitral valves leaflets compared to control. (A,B) 
Representative image of sections stained with 1% alcian blue; and corresponding 
quantification of proteoglycan density (C). Hematoxylin and eosin (H&E) stained sections 
showing the spongiosa layer in degenerative mitral (D) compared to control (E), and the 
corresponding quantification of the spongiosa layer thickness (F). Scale bar = 50μm.
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Figure 4. 
Histological grading of spongiosa layer expansion in degenerative mitral valve leaflets. (A–
D) Representative H&E stained sections of degenerative mitral valve leaflets depicting the 
different grades of spongiosa layer expansion, with grade 3 (D) involving extension into the 
ventricularis layer. Scale bar = 50μm. (E) Bar graph shows the correlation of spongiosa layer 
expansion in thickness (μm) to histological grade severity.
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Figure 5. 
LOX and TGFβ1 expression in degenerative mitral valve leaflets compared to control. (A, 
B) LOX expression in degenerative and control valve leaflets by immunohistochemistry and 
(D, E) by immunofluorescence. (C) Bar graph shows quantification of LOX expression by 
grade from immunohistochemistry images. (F) Linear regression analysis shows a positive 
correlation between mean LOX grade and type I collagen density. (G, H) TGF-β1 
expression in degenerative and control valve leaflets by immunofluorescence; (I) bar graph 
shows corresponding quantification of TGF-β1 expression. Scale bar = 50μm.
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Figure 6. 
Schematic of proposed model of the role of LOX protein in DMVD. The mechanical 
integrity of valve leaflets is dependent on a properly structured extracellular matrix (ECM), 
which is produced by the valvular interstitial cells (VICs). VICs activation and proliferation 
are mediated by genetic abnormalities, growth factors, and mechanical forces. In this study, 
we observed a reduction in type I collagen density, while type III collagen and proteoglycan 
densities were increased resulting in spongiosa layer expansion. In addition, we observed a 
reduction in LOX protein expression, the crucial enzyme involved in collagen cross-linking. 
We speculate that in DMVD, a defective cross-linking of type I collagen by reduced LOX 
protein expression may be associated with disorganization of ECM resulting in disease 
severity.
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Table 1
Demographic and clinical data
Degenerative mitral valve (n=20) Normal valve (control) (n=5) p-value
Age (Years) 51.05 ± 3.6 51.08 ±14.8 0.94
Sex (%) Female 30 40 0.7
Coronary Artery Disease (%) 60 40 0.5
Diabetes Mellitus (%) 60 40 0.5
Hypertension (%) 50 40 0.7
Smoking (%) 60 40 0.5
Blood Glucose (mg/dl) 123.7 ± 6.1 122.0 ± 9.0 0.88
Body Mass Index (kg/m2) 26.1 ± 1.0 23.9± 0.4 0.27
Data are expressed as mean ± SEM, or percentage. Statistical differences between degenerative mitral valve and normal valve (control) groups are 
shown.
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Table 2
Histological Parameters
Degenerative mitral valve (n=20) Normal valve (control) (n=5) p-value
Atrialis Layer Thickness (μm) 324 ± 11.7 93 ± 16.6 0.0001
Spongiosa Layer Thickness (μm) 938 ± 87.1 63 ± 8.9 0.0001
Ventricularis Layer Thickness (μm) 527 ± 26.2 472 ± 25.2 NS
Myxoid area extension into Ventricularis (μm) 0.85 ± 0.1 0.00 0.0001
Grade – severity (0–3) 2.6 ± 0.2 0.00 0.0001
Data are expressed as mean ± SEM. Statistically significant differences between degenerative mitral valve and normal valve (control) groups are 
shown.
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